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Abstract
Objectives Noncardiac findings are common on coronary computed tomography angiography (CCTA). We assessed the clinical
impact of noncardiac findings, and potential changes to surveillance scans with the application of new lung nodule guidelines.
Methods This substudy of the SCOT-HEART randomized controlled trial assessed noncardiac findings identified on CCTA.
Clinically significant noncardiac findings were those causing symptoms or requiring further investigation, follow-up or treat-
ment. Lung nodule follow-up was undertaken following the 2005 Fleischner guidelines. The potential impact of the 2015 British
Thoracic Society (BTS) and the 2017 Fleischner guidelines was assessed.
Results CCTAwas performed in 1,778 patients and noncardiac findings were identified in 677 (38%). In 173 patients (10%) the
abnormal findings were clinically significant and in 55 patients (3%) the findings were the cause of symptoms. Follow-up
imaging was recommended in 136 patients (7.6%) and additional clinic consultations were organized in 46 patients (2.6%).
Malignancy was diagnosed in 7 patients (0.4%). Application of the new lung nodule guidelines would have reduced the number
of patients undergoing a follow-up CT scan: 68 fewer with the 2015 BTS guidelines and 78 fewer with the 2017 Fleischner
guidelines; none of these patients subsequently developed malignancy.
Conclusions Clinically significant noncardiac findings are identified in 10% of patients undergoing CCTA. Application of new
lung nodule guidelines will reduce the cost of surveillance, without the risk of missing malignancy.
Key Points
• Clinically significant noncardiac findings occur in 10% of patients undergoing CCTA.
• Noncardiac findings may be an important treatable cause of chest pain
• Further imaging investigations for noncardiac findings were recommended in 8% of patients after CCTA.
• New lung nodule follow-up guidelines will result in cost savings.
Keywords Computed tomography angiography . Coronary
artery disease . Heart . Incidental findings . Lung neoplasms
Introduction
The SCOT-HEART prospective multicentre randomized con-
trolled trial showed that coronary computed tomography an-
giography (CCTA) in patients with suspected angina due to
coronary heart disease improves diagnostic certainty, changes
management and reduces future rates of myocardial infarc-
tion. [9] This has led to important changes in national guide-
lines which recommend the increased use of CCTA in patients
with stable chest pain [1]. However, CCTA images visualize
more than just the heart, and noncardiac findings can be an
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important cause of symptoms or require further investigation
and management. With the increased use of CCTA, it is im-
portant to understand the downstream consequences of such
noncardiac findings.
The follow-up of incidental lung nodules identified on
computed tomography (CT) is dependent on local, national
and international guidelines. In the SCOT-HEART trial, the
2005 Fleischner Society guidelines [2] were used to provide
recommendations regarding lung nodule follow-up. These
have recently been superseded by the 2015 British Thoracic
Society (BTS) guidelines [3] and the 2017 Fleischner Society
guidelines [4]. Trials of CTscreening in patients at high risk of
lung cancer have also established that CT of the chest can
identify early lung cancers and reduce mortality in a cost-
effective manner [5–7]. CCTA is often performed in patients
with risk factors similar to those screened for lung cancer, such
as smokers over the age of 55 years. Therefore, it is important
to identify lung nodules on CCTAwhich may require further
investigation and management.
In this substudy of the SCOT-HEART trial, we assessed the
frequency and follow-up of noncardiac findings. In addition,
we assessed the impact of changes in lung nodule follow-up
guidelines on downstream investigations and costs.
Materials and methods
Study design and participants
The SCOT-HEART study was a multicentre randomized con-
trol trial of the use of CCTA in outpatients with suspected
angina due to coronary artery disease [8]. The primary results
of the SCOT-HEART study have been published [9]. Briefly,
4,146 patients who attended the Cardiology Outpatient Clinic
were randomized to standard care or CT plus standard care,
and followed up for symptoms, management and outcomes.
Of these, 2,073 patients were randomized to CCTA, of whom
1,778 underwent CCTA. CCTA and non-contrast imaging for
calcium scoring were performed as described previously [9],
and this included a full field of view reconstruction of the
chest in addition to CCTA reconstructions.
Assessment of noncardiac findings
The presence of noncardiac findings was assessed on CCTA
images focused on the heart, and also on the wide field of view
images reconstructed to cover the entire scanned volume. In
patients with partially imaged noncardiac findings identified
at the time of scanning, a further full thoracic scan was not
immediately performed, but could be subsequently recom-
mended by the reporting radiologist. Images were reconstruct-
edwith standard soft tissue and lung reconstruction algorithms
from each scanner. The reporting radiologist used soft tissue,
lung and bone windowing parameters to view the images,
with further manual adjustment as required.
Noncardiac findings were recorded by the reporting radiol-
ogist and the results were provided to the clinical team along
with the CCTA results. Whether noncardiac findings were the
cause of the patient’s symptoms was assessed on a four-point
scale (‘yes’, ‘probable’, ‘unlikely’ or ‘no’). Clinically signifi-
cant noncardiac findings were defined as those causing symp-
toms (‘yes’ or ‘probable’) or incidental findings requiring fur-
ther investigation, follow-up or treatment.
Assessment of lung nodules
Recommendations for lung nodule follow-up were provided
to clinicians according to the 2005 Fleischner Society guide-
lines [2]. We assessed the potential change to the management
of lung nodules if the 2015 BTS guidelines [3] and the 2017
Fleischner Society guidelines had been applied [4]. The lungs
were assessed on wide field of view images reconstructed
using a standard lung reconstruction algorithm. Lung nodule
diameter was measured as the maximum diameter in any
transverse projection, rounded to the nearest millimetre.
Lung nodule volume was determined using Carestream Vue
PACS (version 11; Carestream Health, Rochester, NY).
Follow-up of noncardiac findings
Information on subsequent investigations for noncardiac find-
ings were obtained from electronic health records.
Information on clinic consultations were obtained from elec-
tronic health records or paper records where required. Imaging
costs were obtained from the NHS Reference costs for 2014-
2015 (Table 4) [10].
Statistical analysis
Statistical analysis was performed using SPSS (version 23 for
Mac OS X; IBM Corp., Armonk, NY). Normally distributed
quantitative variables are presented as means and standard
deviations. Non-normally distributed data are presented as
medians and interquartile ranges (IQR). Statistical signifi-
cance was assessed using Student’s t test, the Mann-Whitney
U test or the chi-squared test as appropriate, and relative risks
(RR) were calculated. A statistically significant difference was
defined as a two-sided p value of <0.05.
Results
Noncardiac findings
Of the 1,778 patients who underwent CCTA, noncardiac find-
ings were reported in 675 (38%). Patients with noncardiac
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findings were slightly older (60 ± 9 vs. 56 ± 9 years; p <
0.001) but there were no differences in gender, body mass
index or presence of diabetes mellitus (Table 1). Patients
who were current smokers or ex-smokers were more likely
to have noncardiac findings than nonsmokers (RR 1.38,
95% confidence interval, CI, 1.22–1.56; p < 0.001). Patients
with moderate or obstructive coronary artery disease were
slightly more likely to have noncardiac findings than patients
with mild disease or normal coronary arteries (RR 1.18, 95%
CI 1.05–1.34; p = 0.005).
In 175 of the 675 patients with noncardiac findings, the
findings were defined as clinically significant (10% of all
those undergoing CCTA, and 26% of those with noncardiac
findings). There were no differences in age, gender, body
mass index, presence of diabetes mellitus or presence of ob-
structive coronary artery disease between those with signifi-
cant and those with nonsignificant noncardiac findings. The
commonest findings were lung nodules or masses, emphyse-
ma and hiatus hernia (Table 2, Fig. 1). Noncardiac findings
were deemed to be the definite cause of symptoms in 22 pa-
tients (1.2% of those undergoing CCTA, and 3.3% of those
with noncardiac findings), and the probable cause of symp-
toms in a further 33 patients (1.9% and 4.9%, respectively).
This included five patients (0.3% of those undergoing CCTA)
with pulmonary emboli (Fig. 2).
Investigation and management of noncardiac
findings
Further imaging investigations for noncardiac findings were
performed in 136 patients (7.6% of those undergoing CCTA,
20% of those with noncardiac findings). The most frequent
follow-up imagingwas CT for lung nodule assessment follow-
ed by ultrasonography of the liver and CT follow-up of other
noncardiacfindings(Table3).Smokerswereslightlymore like-
ly to undergo follow-up imaging (RR 1.41, 95%CI 1.02–1.96;
p = 0.04), but there were no differences in rates of follow-up in
relation to age, body-mass index, presence of diabetesmellitus
or presence of obstructive coronary artery disease.
Additional clinic consultations were organized in 46 pa-
tients (2.6% of those undergoing CCTA, 7% of those with
noncardiac findings). The most frequent specialty to which
patients were referred was the respiratory clinic (Table 3).
There were no differences between patients who did or did
not have follow-up in terms of age, bodymass index, presence
of diabetes mellitus, smoking status or presence of obstructive
coronary artery disease.
Patients with respiratory infection, pulmonary embolism
and malignancy identified on CCTA received appropriate
therapy. In two patients with malignancy, the disease was
too advanced at presentation and palliative management was
given. The remaining patients underwent surgery (one pa-
tient), chemotherapy (one), chemotherapy and radiotherapy
(one), pleurodesis (one), and chemoembolization (one). In
contrast, there was no increase in gastric acid suppressant
medication (RR 0.84, 95% CI 0.53–1.34; p = 0.466) in pa-
tients with a hiatus hernia nor were there demonstrable chang-
es to treatment in patients with emphysema.
Outcomes of patients with non-cardiac findings
Malignancy was diagnosed in seven patients who underwent
investigation for noncardiac findings (0.4% of patients under-
going CCTA, 3.5% of those with lung nodules). Malignancies
included lung cancer (four patients) (Fig. 3), mesothelioma
(one), metastatic testicular cancer (one) and hepatocellular
carcinoma (one; Fig. 2). In patients with clinically significant
noncardiac findings, there was no statistically significant dif-
ference in all-cause mortality (RR 2.50, 95% CI 0.70–8.87; p
= 0.157).
Lung nodules
Lung nodules, masses or granuloma were identified on CCTA
in 200 patients (11% of those undergoing CCTA): ≤4 mm in
119 (60%), 5–7 mm in 58 (29%) and ≥8 mm in 23 (12%).
Lung nodules were more common in current smokers or ex-
smokers (RR 1.58, 95% CI 1.20–2.08; p = 0.001) but were not
associated with age, gender, or presence of obstructive
Table 1 Baseline patient
characteristics Non-cardiac finding
absent
Non-cardiac finding
present
p value
Number of patients 1,103 675
Age (years), mean ± SD 56 ± 9 59 ± 9 <0.001
Male, n (%) 626 (57) 372 (55) 0.522
BMI (kg/m2), mean ± SD 29.7 ± 5.7 29.5 ± 5.5 0.353
Smoking status, n (%) Nonsmoker 580 (53) 268 (40) <0.001
Ex-smoker 324 (29) 271 (40)
Current smoker 199 (18) 135 (20)
Diabetes mellitus, n (%) 128 (12) 68 (10) 0.349
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coronary artery disease. In 118 (59%) of the patients with lung
nodules, semiautomated measurement of nodule volume was
possible. The median lung nodule volume was 55 mm3 (IQR
32–116 mm3). Volume measurements were not possible in the
remaining patients due to the small size of the lesions, prox-
imity to structures of similar density, such as the pleura or
diaphragm, or technical reasons.
Follow-up imaging for lung nodule assessment was recom-
mended in 126 patients (7% of those undergoing CCTA). One
patient died before follow-up imaging could be performed and
40 patients (20% of those with lung nodules) did not undergo
follow-up imaging due to physician or patient choice. Thus 85
patients (4.7% of those undergoing CCTA) underwent CT
follow-up for lung nodules. The median follow-up duration
was 12 months (IQR 7–19 months) and the median number of
CT scans performed was 1 (IQR 1–2). The first follow-up CT
scan was performed at a median of 7 months after the initial
CCTA scan (IQR 3.5–9.0 months), the second at 14 months
(IQR 10.3–20.8 months), the third at 24 months (IQR 15–25.5
months) and the fifth at 31 months (IQR 26.8–35.3 months).
Application of new lung nodule guidelines
The 2015 BTS guidelines suggest that no follow-up is re-
quired for lung nodules <5 mm or <80 mm3. In the SCOT-
HEART study, this means that 68 fewer scans would have
been performed in 47 patients, all of whomwere subsequently
discharged from follow-up without evidence of malignancy.
This would have reduced the number of patients with signif-
icant lung nodules requiring follow-up to 38 (2% of patients
undergoing CCTA). The 2017 Fleischner Society guidelines
Table 2 The frequency of noncardiac findings in patients undergoing
CCTA for suspected angina due to coronary heart disease
System Finding Frequency
Lung Emphysema or other parenchymal changes 202
Lung mass/nodule/granuloma 200
Atelectasis/scarring 63
Pleural plaque 29
Bronchiectasis 22
Fibrosis 17
Consolidation or pneumonia 15
Pulmonary embolism 4
Pleural effusion 3
Mediastinum Lymphadenopathy 30
Calcified lymph nodes 16
Aorta Atheroma 26
Dilation 17
Breast Nodule 5
Liver Cysts 36
Haemangioma 2
Fatty infiltration 2
Oesophagus Hiatus hernia 121
Thickening 3
Other Anterior mediastinal mass, arteriovenous malformation,
Bochdalek hernia, broncocele, duplication cyst, elevated left
hemidiaphragm, gallstones, hamartoma, pericardial cyst,
sclerotic vertebrae, syndesmophytes, subclavian vein
stenosis, splenomegaly, splenic artery aneurysm, vertebral
wedge fractures
Fig. 1 Examples of noncardiac
findings identified on CCTA: a
abnormal contrast enhancement
in the liver (arrow) diagnosed as a
benign haemangioma on
subsequent imaging; b enlarged
lymph node (arrow); c
intrathoracic stomach; d
centrilobular emphysema
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suggest that no follow-up is required for lung nodules of
<6 mm or <100 mm3. In the SCOT-HEART study this means
that 78 fewer scans would have been performed in 53 patients,
all of whom were subsequently discharged from follow-up
without evidence of malignancy. This would have reduced
the number of patients with significant lung nodules requiring
follow-up to 32 (2% of patients undergoing CCTA).
The cost of follow-up imaging for noncardiac findings was
£10.06 per patient undergoing CCTA (1,778 patients,
Table 4). The cost of imaging for lung nodule follow-up was
£147.25 per patient undergoing lung nodule follow-up (85
patients) and £7.04 per patient undergoing CCTA (1,778
patients, Table 5). Applying the 2015 BTS guidelines would
have reduced the cost per patient undergoing CCTA to £3.52
and applying the 2017 Fleischner Society guidelines would
have reduced the cost to £3.00. This equates to 50% and 57%
reductions in cost, respectively (Table 5).
Discussion
Although noncardiac findings on CCTA are common, only
one quarter of these are clinically significant. Occasionally,
these findings identify an important treatable cause of the
patient’s chest pain but usually they represent important
incidental findings that require surveillance, especially lung
nodules. The application of new guidelines for lung nodule
assessment will reduce the number of follow-up CT scans
required in these patients, without the risk of missing malig-
nancy identified during screening, and will significantly re-
duce the cost of follow-up imaging.
Frequency and implications of noncardiac findings
The frequency of noncardiac findings in patients undergoing
CCTA varies widely, and depends on the classification of
findings and the population profile, such as age and frequency
of smoking habit. A systematic review identified an average
prevalence of 41% for noncardiac findings and 16% for clin-
ically significant findings [11]. Our rates of noncardiac find-
ings and significant findings were similar but slightly lower at
38% and 10%, respectively. This was possibly due to the wide
inclusion criteria of the SCOT-HEARTstudy, and the focus on
a narrow detector range reducing both radiation dose and the
scanned body volume.
Causes of chest pain can be challenging to diagnose. Patients
in the SCOT-HEART trial were referred because of concern that
they had angina pectoris due to coronary heart disease. In the
CCTAgroup,ultimately696patients (33%)werediagnosedwith
this condition. In contrast, only a further 55 patients (3%) were
Fig. 2 Examples of pulmonary
emboli identified on CCTA in two
patients (arrows)
Table 3 Follow-up investigations
and clinic consultations for
noncardiac findings identified in
patients undergoing CCTA
Follow-up investigations Follow-up clinic consultations
Investigation Frequency Clinic Frequency
CT follow-up of other findings 12 Surgery 4
CT follow-up for lymphadenopathy 7 Oncology 3
PET/CT 4 Gastrointestinal 2
Chest plain radiography 6 Urology 2
Breast ultrasonography and mammography 4
Liver MRI 2
MRI for vascular assessment 1
MRI for other findings 1
Isotope bone scan 1
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diagnosed with alternative conditions that accounted for their
symptoms including pneumonia, pulmonary embolismand can-
cer. This suggests a very modest rate of noncardiac causes of
chest pain in thispopulation.However, someof thesenoncardiac
causes of chest pain are serious and potentially life-threatening,
underlining the importance of full and comprehensive scan
reporting including noncardiac structures.
Lung nodule follow-up
The lungs were the commonest location of noncardiac find-
ings in the SCOT-HEARTstudy. This is similar to the findings
of previous studies [11] and was largely driven by the preva-
lence of emphysema and lung nodules. The link between car-
diovascular disease and respiratory diseases, such as emphy-
sema, is complex and includes shared risk factors such as
smoking and chronic inflammation [12, 13]. Lung cancer is
the most frequent cause of death from cancer worldwide [5].
The National Lung Screening Trial (NLST) recruited asymp-
tomatic participants aged 55 to 74 years, with a 30 pack-year
smoking history and who were current smokers or had
stopped smoking in the previous 15 years. The NLST identi-
fied a 20% (95% CI 6.8–26.7; p = 0.004) relative reduction in
lung cancer mortality among 26,722 patients undergoing low-
dose CT screening as compared with 26,732 patients under-
going plain radiography chest screening [14].
The NELSON study recruited 15,822 patients aged 50 to 75
years, who had smoked ≥15 cigarettes per day for ≥25 years or
≥10 cigarettes per day for ≥30 years and who were current
smokers or had ceased smoking in the previous 10 years [15].
Participants were randomized 1:1 to CT screening or standard
care. Early reports identified a beneficial effect of a screening
interval of 2 years compared with 2.5 years [6], but at the time
of this report the full trial results were awaited. The UK Lung
Cancer Screening (UKLS) trial recruited 249,988 participants
aged50 to75yearswhohada≥5%5-year lung cancer riskbased
on the Liverpool Lung Project version 2 risk prediction model
[7].Participantswererandomized1:1toCTscreeningorstandard
care. Pilot results showed that lung cancer could be identified at
anearly stagewithpotentially curative treatment possible in over
80% of patients [7]. However, at the time of this report the full
results were also awaited.
The US Preventive Services Task Force recommends an-
nual CT lung cancer screening in people aged 55 to 80 years,
with a 30 pack-year history, and who were current smokers or
had stopped smoking within the past 15 years [16]. The pro-
portion of patients with lung nodules in the SCOT-HEART
study was lower than in the lung cancer screening trials. This
is probably partly due to the lower risk in the SCOT-HEART
population, which included younger patients and nonsmokers.
Table 4 Cost (in UK pounds sterling) of imaging performed to investigate noncardiac findings in the 1,778 patients who underwent CCTA. Cost per
scan was taken from NHS reference costs for 2014-2015 [10]
Investigation Number of patients Number of scans Cost per scan (£) Total cost per imaging modality (£)
CT chest for lung nodule follow-up 85 136 92.03 12,516.08
CT chest for other follow-up 10 11 104.07 1,144.77
CT chest, abdomen 1 1 120.92 120.92
CT chest, abdomen, pelvis 5 6 124.53 747.18
CT abdomen, pelvis 2 2 120.92 241.84
CT chest, neck 1 1 120.92 120.92
Liver ultrasonography 17 17 53.74 913.58
PET/CT 4 4 194.37 777.48
Chest plain radiography 6 6 30.00 180.00
Breast ultrasonography and mammography 4 4 53.74 214.96
Liver MRI 2 2 181.76 363.52
Other MRI 2 2 181.76 363.52
Isotope bone scan 1 1 188.77 188.77
Total cost of follow-up imaging (£) 17,893.54
Cost per patient for 1,778 patients undergoing CCTA (£) 10.06
Fig. 3 Example of lung cancer on a full field of view image
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In addition, only part of the lungs are imaged on the wide field
of view reconstruction fromCCTA images as the scan range is
selected to cover just the length of the heart rather than the full
thorax. CCTA therefore does not image the upper parts of the
lungs, a frequent location for lung cancer [17].
New lung nodule follow-up guidelines
The new revised lung nodule follow-up guidelines have
changed the threshold for lung nodules that require follow-
up. In the 2015 BTS guidelines, no follow-up is required for
Bclearly benign lesions^, lesions <5mmmaximum diameter or
lesions <80 mm3 volume [3]. In the 2017 Fleischner guide-
lines, no follow-up is required for single nodules <6 mm aver-
age diameter or <100 mm3 volume, but nodules with
Bsuspicious^ morphology or located in the upper lobe may
be considered for a follow-up scan at 12 months [4]. Both
new guidelines include the assessment of lung nodule volume
rather than diameter as a potentially more reproducible method
of assessment [4]. However, the value of automated lung nod-
ule volume measurement is limited as only 59% of patients
with lung nodules could be assessed in our study. In addition,
whether maximum or average diameter is used may also affect
the results. We retrospectively applied these diameter and vol-
ume criteria to the SCOT-HEART data which means we may
have underestimated the benefit of the 2015 BTS guidelines
and overestimated the benefit of the 2017 Fleischer guidelines.
Nevertheless, we have shown that the application of these
guidelines would lead to significant cost savings.
Previous studies have shown that the direct cost of imaging
for significant incidental findings are between US$438 and
US$606 [11, 18, 19]. The cost of follow-up imaging for sig-
nificant noncardiac findings was lower in the SCOT-HEART
study than in previous studies with a cost per patient of £10.06
averaged across all patients undergoing CCTA. However,
there were significant differences in the healthcare systems
involved in previous studies and therefore these figures are
not directly comparable. There may also have been differences
in the classification of significant noncardiac findings, in –the
estimation of costs and in follow-up guidelines. In addition,
the total cost of follow-up in the SCOT-HEART study should
also include downstream clinic attendances and other
nonimaging investigations which were not included in this
estimate. The use of the national picture archiving system
(PACS), that has been available in Scotland since 2008, for
follow-up imaging means that any imaging performed in
Scotland can be identified. However, a small number of pa-
tients may be missing if they have moved out of Scotland.
It is interesting to note that 20% of patients in whom sub-
sequent imaging for lung nodule assessment was recommend-
ed did not undergo further imaging. This is a limitation of this
study, but does highlight the real-world implications of the
identification of noncardiac findings on CCTA. A variety of
factors have been found to influence referral for further imag-
ing including patient and physician factors [20].
Conclusions
Significant noncardiac findings occur in 10% of patients un-
dergoing CCTA for suspected angina due to coronary heart
disease. Occasionally, these findings identify an important
treatable cause of the patient’s chest pain but usually they
represent important incidental findings that require surveil-
lance, especially lung nodules. The application of new guide-
lines for lung nodule assessment will reduce the number of
follow-up CT scans required in these patients, without the risk
of missing malignancy identified during screening, and will
significantly reduce the cost of follow-up imaging.
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